Cell Line Engineering for Cell and Gene Therapy

NewBiologix is at the forefront of advancing gene therapy and cell therapy technologies, focusing on making these life-saving treatments more accessible and affordable. The company has developed a pioneering stable inducible rAAV (recombinant adeno-associated virus) producer cell line platform, which addresses the limitations of traditional transient transfection methods commonly used in gene therapy manufacturing. By creating stable cell lines that can efficiently produce viral vectors at scale, NewBiologix aims to enhance production reliability, reduce timelines, and lower costs, ultimately facilitating faster patient access to therapies. Their commitment to developing high-quality, high-purity rAAVs is central to their mission of revolutionizing the gene therapy landscape.

The recently launched Xcell™ Portfolio exemplifies NewBiologix's innovative approach, featuring a high-performance engineered HEK293 cell line specifically designed for rAAV production, alongside an advanced platform for streamlining the production and testing of rAAV candidates. Additionally, the portfolio includes customized genomic analytical tools for quality assessment. By integrating these advanced technologies, NewBiologix is not only accelerating the development of rAAVs at the preclinical stage but also addressing the complex challenges in gene therapy production. This strategic focus positions NewBiologix to significantly impact the future of gene therapy, ensuring that safe and effective treatments are available to a broader patient population.

Switzerland

Based in Lausanne, Switzerland, NewBiologix SA is a technology innovation company developing a proprietary and breakthrough DNA integration platform for the advanced engineering of human and mammalian cell lines for the improved production of viral vectors used in gene therapies.

NewBiologix

Company Details